The DOI matches its Crossref record; 32 of the 34 references it cites were found in a registry or an index.
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Open accessAbstract
Alzheimer’s disease is the world’s most common dementing illness. Deposition of amyloid-β peptide drives cerebral neuroinflammation by activating microglia. Indeed, amyloid-β activation of the NLRP3 inflammasome in microglia is fundamental for interleukin-1β maturation and subsequent inflammatory events. However, it remains unknown whether NLRP3 activation contributes to Alzheimer’s disease in vivo. Here we demonstrate strongly enhanced active caspase-1 expression in human mild cognitive impairment and brains with Alzheimer’s disease, suggesting a role for the inflammasome in this neurodegenerative disease. Nlrp3−/− or Casp1−/− mice carrying mutations associated with familial Alzheimer’s disease were largely protected from loss of spatial memory and other sequelae associated with Alzheimer’s disease, and demonstrated reduced brain caspase-1 and interleukin-1β activation as well as enhanced amyloid-β clearance. Furthermore, NLRP3 inflammasome deficiency skewed microglial cells to an M2 phenotype and resulted in the decreased deposition of amyloid-β in the APP/PS1 model of Alzheimer’s disease. These results show an important role for the NLRP3/caspase-1 axis in the pathogenesis of Alzheimer’s disease, and suggest that NLRP3 inflammasome inhibition represents a new therapeutic intervention for the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rat research has identified the NLRP3-ASC inflammasome as a major mechanism through which microglia may drive pathological features of AD [92,93,94].”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both beta-amyloids and tau can activate the NLRP3-ASC inflammasome within microglia [92,93].”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The nucleotide-binding oligomerization domain-like receptor, pyrin domain-containing 3 (NLRP3), within microglia recruits the adaptor protein apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain (ASC) to form an inflammasome complex.”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In APP/PS1 mice model, NLRP3 knockout reduced Aβ deposition by enhancing phagocytic clearance capacity and increasing extracellular Aβ degradation by insulin- degrading enzyme (IDE).354”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [354]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of hippocampal NLRP3 inflammasome-mediated pyroptosis is associated with neuronal damage, cognitive decline, and neuronal death (Hanslik & Ulland, 2020; Heneka et al., 2013; Ising et al., 2019; Venegas et al., 2017).”
From Picroside II Alleviates the Progression of Alzheimer’s Disease via the NLRP3/Caspase-1/GSDMD Pathway (2025) · cites this paper as Heneka et al., 2013
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NLRP3 or caspase-1 knockdown in AD mouse models has yielded promising results in decreasing Aβ accumulation, improving spatial memory, and alleviating other AD-related symptoms (Heneka et al., 2013).”
From Picroside II Alleviates the Progression of Alzheimer’s Disease via the NLRP3/Caspase-1/GSDMD Pathway (2025) · cites this paper as Heneka et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ablation of Nlrp3 or Casp1 in APP/PS1 mice rescued spatial memory and behavioral deficits, LTP suppression and spine loss observed in these mice [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, another study reported strongly increased levels of active caspase-1 in early-onset AD and LOAD patients as well as in MCI individuals [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This inflammasome complex is responsible for the production of IL-1 beta, which is a proinflammatory cytokine.”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“IL-1 beta was shown to exacerbate tau pathologies [97] and reduce microglial phagocytic activity [92,93,94].”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, microglial function may also be of relevance to cognitive performance, as suggested by recent experimental data, which showed that improved microglial clearance was protective in terms of memory function (17).”
From SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease (2014) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Proinflammatory environments and signalling are a prominent observation in AD brain pathology [39].”
From Heterozygous expression of the Alzheimer’s disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses (2022) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“Inhibiting or downregulating the NLRP3 inflammasome ameliorates AD neuropathology in animal models, which opens up a therapeutic avenue for modulators of NLRP3 activation in AD.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“APP/PS1/Nlrp3−/− and APP/PS1/Casp1−/− mice also displayed decreased Aβ plaque deposition, suggesting that NLRP3 inflammasome activation impairs microglial capacity to clear Aβ [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“APP/PS1/Nlrp3−/− and APP/PS1/Casp1−/− mice also displayed decreased Aβ plaque deposition, suggesting that NLRP3 inflammasome activation impairs microglial capacity to clear Aβ [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“The decreased plaque deposition was also related to increased levels of the proteolytic enzyme insulin-degrading enzyme (IDE) [77], previously reported to degrade Aβ [83].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“NLRP3 deficiency reduces amyloid deposition and rescues memory deficits in the APP/PS1 model of AD [18].”
From 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) · cites this paper as [18]
In the citing paper
“One of the key biological functions of CASP1 is the cleavage of prointerleukin-1β (IL-1β) into the mature biological active cytokine, which is largely overexpressed in brains of patients with AD.44”
From APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease (2016) · cites this paper as [44]
In the citing paper
“Preclinical studies support the concept that CASP1-directed increase of IL-1β can augment the deposition of β-amyloid within the brain to worsen Alzheimer's symptoms.44”
From APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease (2016) · cites this paper as [44]
In the citing paper
“CASP1, an essential component of NLPR3 inflammasomes, encodes a cysteine protease that is largely overexpressed in brains of patients with AD.44”
From APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease (2016) · cites this paper as [44]
In the citing paper
“Notably, Aβ also can activate NF-κB signaling and the NLRP3-ASC inflammasome [426, 427], suggesting that Aβ and tau share common mechanisms in microglia activation.”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [427]
In the citing paper
“The NLRP3 inflammasome is critical for maturation of IL-1β, and loss of NLRP3 in APP/PS1 decreased amyloid burden (131).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [131]
In the citing paper
“Microglia express multiple receptors that can bind Aβ and trigger inflammation, such as CD36 (105), TLR2, TLR4, TLR6 (17), and NLRP3 (106)”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [106]
In the citing paper
“NLRP3 and caspase-1 genetic deletion results in decreased Aβ deposition, reduced IL-1β release from microglia and improved cognitive performance in APPPS1 mice (Heneka et al., 2013).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Heneka et al., 2013
In the citing paper
“Toll-like receptors and NOD-like receptors have been previously implicated in the microglia response to Aβ accumulation and shown to mediate an inflammatory response that contributes to pathology”
From TREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease (2017) · cites this paper as Heneka et al., 2013
In the citing paper
“ITGAM/CD11b (or CR3A), is a cell surface receptor involved in activation, migration and phagocytosis of immune cells, so much so that ITGAM/CD11b is used as a marker of activated microglia (Matsuoka et al., 2001; Heneka et al., 2013; Kamphuis et al., 2016).”
From Genetic variability in response to amyloid beta deposition influences Alzheimer’s disease risk (2019) · cites this paper as Heneka et al., 2013
In the citing paper
“Animal studies confirmed this significant involvement of NLRP activation, as APP/PS1 mice, lacking the expression of ASC, caspase-1, or NLRP3 had significantly reduced hippocampal and cortical amyloid plaque deposition and ameliorated disease outcome (229, 230).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [230]
In the citing paper
“Recently, an alternative pathway has been described for intracellular signaling produced by the binding of Aβ to microglial cells, activating NLRP3 inflammasome (Heneka et al., 2013; Sheedy et al., 2013).”
From The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma. (2017) · cites this paper as Heneka et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566
The NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Self-citationThe Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Li, P., Allen, H., Banerjee, S., Franklin, S., Herzog, L., Johnston, C. G., McDowell, J., Paskind, M. P., Rodman, L., Salfeld, J. G., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90490-5 · Cited by 1,408
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 1×
“Cytokines, including IL-1 β , were found to impair microglial clearance functions 16,17 .”
Bevins, R. A., & Besheer, J. (2006) · Nature Protocols · doi:10.1038/nprot.2006.205 · Cited by 1,278
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3
Kanneganti, T., Özören, N., Body–Malapel, M., Amer, A. O., Park, J., Franchi, L., Whitfield, J. R., Barchet, W., Colonna, M., Vandenabeele, P., et al. (2006) · Nature · doi:10.1038/nature04517 · Cited by 1,149
Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice
Chapman, P. F., White, G. L., Jones, M. W., Cooper-Blacketer, D., Marshall, V. J., Irizarry, M., Younkin, L., Good, M. A., Bliss, T. V. P., Hyman, B. T., et al. (1999) · Nature Neuroscience · doi:10.1038/6374 · Cited by 946
El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., & Luster, A. D. (2007) · Nature Medicine · doi:10.1038/nm1555 · Cited by 915
Flagged first, then by citations
2 of the 34 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 601–700 of 1,031
Yang, S., Xia, C., Li, S., Du, L., Zhang, L., & Zhou, R. (2014) · Redox Biology · doi:10.1016/j.redox.2014.04.001 · Cited by 88
The NLRP3 Inflammasome as a Critical Actor in the Inflammaging Process
Sebastian-Valverde, M., & Pasinetti, G. M. (2020) · Cells · doi:10.3390/cells9061552 · Cited by 90
Tang, M., Liu, T., Jiang, P., & Dang, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105586 · Cited by 88
The role of caspase-8 in inflammatory signalling and pyroptotic cell death
Pang, J., & Vince, J. E. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101832 · Cited by 90
Mohamed, I., Ishrat, T., Fagan, S. C., & El‐Remessy, A. B. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.6126 · Cited by 88
Microglia communication: parallels between aging and Alzheimer's disease
Udeochu, J. C., Shea, J. M., & Villeda, S. A. (2016) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12307 · Cited by 87
Inflammasome-Derived Exosomes Activate NF-κB Signaling in Macrophages
Zhang, Y., Liu, F., Yuan, Y., Jin, C., Chang, C., Zhu, Y., Zhang, X., Tian, C., He, F., & Wang, J. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00599 · Cited by 88
Friend, Foe or Both? Immune Activity in Alzheimer’s Disease
Frost, G. R., Jonas, L. A., & Li, Y. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00337 · Cited by 88
Natural compounds flavonoids as modulators of inflammasomes in chronic diseases
Owona, B. A., Abia, W. A., & Moundipa, P. F. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106498 · Cited by 88
Key Mechanisms and Potential Targets of the NLRP3 Inflammasome in Neurodegenerative Diseases
Guan, Y., & Han, F. (2020) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2020.00037 · Cited by 90
Moya, G. E., Rivera, P. D., & Dittenhafer‐Reed, K. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137030 · Cited by 90
Electrophilic Warhead-Based Design of Compounds Preventing NLRP3 Inflammasome-Dependent Pyroptosis
Cocco, M., Garella, D., Stilo, A. D., Borretto, E., Stevanato, L., Giorgis, M., Marini, E., Fantozzi, R., Miglio, G., & Bertinaria, M. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501072b · Cited by 87
Metabolic Dysfunction in Alzheimer’s Disease: From Basic Neurobiology to Clinical Approaches
Clarke, J. R., Ribeiro, F. C., Frozza, R. L., Felice, F. G. D., & Lourenco, M. V. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179911 · Cited by 93
Wang, Y., Wang, M., Xu, M., Li, T., Fan, K., Yan, T., Xiao, F., Bi, K., & Jia, Y. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.042 · Cited by 86
NLRP3 polymorphisms are associated with late-onset Alzheimer's disease in Han Chinese
Tan, M., Yu, J., Jiang, T., Zhu, X., Wang, H.-F., Zhang, W., Wang, Y., Jiang, W., & Tan, L. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.10.002 · Cited by 89
TREM2‐dependent effects on microglia in Alzheimer's disease
Zhou, Y., Ulland, T. K., & Colonna, M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00202 · Cited by 82
Apolipoprotein E4 and meningeal lymphatics in Alzheimer disease: a conceptual framework
Mentis, A. A., Dardiotis, E., & Chrousos, G. P. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0731-7 · Cited by 83
de Dios, C., Abadin, X., Roca-Agujetas, V., Jimenez-Martinez, M., Morales, A., Trullas, R., Mari, M., & Colell, A. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00343-3 · Cited by 85
Ruan, Y., Xiong, Y., Fang, W., Yu, Q., Mai, Y., Cao, Z., Wang, K., Lei, M., Xu, J., Liu, Y., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01524-4 · Cited by 85
“It is well established that Aβ deposition in AD drives neuroinflammation via activating NLRP3 inflammasomes [52, 58].”
BackgroundHe, J., Zhao, X., Xu, L., & Mao, C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190764 · Cited by 88
Lactic Acid Fermentation Is Required for NLRP3 Inflammasome Activation
Lin, H., Chen, Y.-J., Wei, Y., Lin, H., Chen, C., Liu, T., Hsieh, Y.-L., Huang, K., Lin, K., Wang, H.-H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.630380 · Cited by 91
Precision Nutrition for Alzheimer’s Prevention in ApoE4 Carriers
Norwitz, N. G., Saif, N., Ariza, I. E., & Isaacson, R. (2021) · Nutrients · doi:10.3390/nu13041362 · Cited by 92
Role of Extracellular Vesicles in Cell Death and Inflammation
Sanwlani, R., & Gangoda, L. (2021) · Cells · doi:10.3390/cells10102663 · Cited by 90
Targeting NLRP3 Inflammasome With Nrf2 Inducers in Central Nervous System Disorders
Tastan, B., Arioz, B. I., & Genç, Ş. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.865772 · Cited by 87
Micheli, L., Bertini, L., Bonato, A., Villanova, N., Caruso, C., Caruso, M., Bernini, R., & Tirone, F. (2023) · Nutrients · doi:10.3390/nu15071767 · Cited by 91
Thakkar, R., Wang, R., Sareddy, G. R., Wang, J., Thiruvaiyaru, D. S., Vadlamudi, R. K., Zhang, Q., & Brann, D. W. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/8309031 · Cited by 84
Inflammasome assembly in neurodegenerative diseases
Singh, J., Habean, M. L., & Panicker, N. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.07.009 · Cited by 83
Zhu, G., Zhao, J., Wang, G., & Chen, W. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c00652 · Cited by 84
Recent Progress in Alzheimer’s Disease Research, Part 1: Pathology
Hane, F. T., Lee, B. Y., & Leonenko, Z. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160882 · Cited by 92
Wu, P.-J., Hung, Y.-F., Liu, H., & Hsueh, Y. (2017) · NeuroImmunoModulation · doi:10.1159/000477092 · Cited by 85
Chen, C., Wei, Y.-Z., He, X., Li, D., Wang, G., Li, J.-J., & Zhang, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00936 · Cited by 85
Pirzada, R. H., Javaid, N., & Choi, S. (2020) · Genes · doi:10.3390/genes11020131 · Cited by 84
Wang, C., Gao, Y., Zhang, Z., Chen, C., Chi, Q.-J., Xu, K., & Yang, L. (2020) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2020.110568 · Cited by 88
Circadian Control of Inflammasome Pathways: Implications for Circadian Medicine
Pourcet, B., & Duez, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01630 · Cited by 88
Plasma-borne indicators of inflammasome activity in Parkinson’s disease patients
Anderson, F. L., von Herrmann, K. M., Andrew, A. S., Kuras, Y. I., Young, A. L., Scherzer, C. R., Hickey, W. F., Lee, S., & Havrda, M. C. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-020-00147-6 · Cited by 89
Decoding Mast Cell-Microglia Communication in Neurodegenerative Diseases
Sandhu, J. K., & Kulka, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031093 · Cited by 90
Ratan, Y., Rajput, A., Maleysm, S., Pareek, A., Jain, V. K., Pareek, A., Kaur, R., & Singh, G. (2023) · Biomedicines · doi:10.3390/biomedicines11051398 · Cited by 89
Network-wide dysregulation of calcium homeostasis in Alzheimer’s disease
Brawek, B., & Garaschuk, O. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1798-8 · Cited by 83
Gao, J., Cui, J. Z., To, E., Cao, S., & Matsubara, J. A. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1062-3 · Cited by 83
Khan, N., Kuo, A., Brockman, D. A., Cooper, M. A., & Smith, M. T. (2017) · Inflammopharmacology · doi:10.1007/s10787-017-0401-9 · Cited by 88
Proteostasis Disturbances and Inflammation in Neurodegenerative Diseases
Sonninen, T.-M., Goldsteins, G., Laham-Karam, N., Koıstınaho, J., & Lehtonen, Š. (2020) · Cells · doi:10.3390/cells9102183 · Cited by 89
Zinc Status Alters Alzheimer's Disease Progression through NLRP3-Dependent Inflammation
Rivers‐Auty, J., Tapia, V. S., White, C., Daniels, M. J. D., Drinkall, S., Kennedy, P. T., Spence, H. G., Yu, S., Green, J., Hoyle, C., et al. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.1980-20.2020 · Cited by 87
Self-citationKuwar, R., Rolfe, A., Di, L., Blevins, H., Xu, Y., Sun, X., Bloom, G. S., Zhang, S., & Sun, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210400 · Cited by 82
Qiao, C., Zhang, L., Sun, X., Ding, J., Lu, M., & Hu, G. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9980-5 · Cited by 84
Naia, L., Shimozawa, M., Bereczki, E., Li, X., Liu, J., Jiang, R., Giraud, R., Leal, N. S., Pinho, C. M., Berger, E., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02289-4 · Cited by 79
Burm, S. M., Zuiderwijk-Sick, E. A., ‘t Jong, A. E. J., van der Putten, C., Veth, J., Kondova, I., & Bajramovic, J. J. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2510-14.2015 · Cited by 82
Greve, H. J., Dunbar, A. L., Lombo, C. G., Ahmed, C., Thang, M., Messenger, E. J., Mumaw, C. L., Johnson, J. A., Kodavanti, U. P., Oblak, A. L., et al. (2023) · Brain · doi:10.1093/brain/awac113 · Cited by 82
Litwiniuk, A., Bik, W., Kalisz, M., & Baranowska-Bik, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115603 · Cited by 82
The Evolving Biology of Microglia in Alzheimer's Disease
Malm, T. M., Jay, T. R., & Landreth, G. E. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0316-8 · Cited by 85
Korean red ginseng extracts inhibit NLRP3 and AIM2 inflammasome activation
Kim, J., Ahn, H., Han, B.-C., Lee, S., Cho, Y., Kim, C. H., Hong, E., An, B., Jeung, E., & Lee, G. (2014) · Immunology Letters · doi:10.1016/j.imlet.2013.12.017 · Cited by 82
Thundyil, J., & Lim, K. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.11.003 · Cited by 85
Early Life Stress and Epigenetics in Late-onset Alzheimer’s Dementia: A Systematic Review
Lemche, E. (2018) · Current Genomics · doi:10.2174/1389202919666171229145156 · Cited by 84
Denver, P., & McClean, P. L. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.238608 · Cited by 89
Yi, Y. (2019) · Immunology · doi:10.1111/imm.13134 · Cited by 85
Neurodegeneration and NLRP3 inflammasome expression in the anterior thalamus of SOD1(G93A) ALS mice
Debye, B., Schmülling, L., Zhou, L., Rune, G., Beyer, C., & Johann, S. (2018) · Brain Pathology · doi:10.1111/bpa.12467 · Cited by 81
Hashemiaghdam, A., & Mroczek, M. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577185 · Cited by 79
Targeting NLRP3 Inflammasome Reduces Age-Related Experimental Alveolar Bone Loss
Zang, Y., Song, J. H., Oh, S., Kim, J. W., Lee, M. N., Piao, X., Yang, J.-W., Kim, O. S., Kim, T. S., Kim, S. H., et al. (2020) · Journal of Dental Research · doi:10.1177/0022034520933533 · Cited by 81
Trained immunity: induction of an inflammatory memory in disease
Schlüter, T., van Elsas, Y., Priem, B., Ziogas, A., & Netea, M. G. (2025) · Cell Research · doi:10.1038/s41422-025-01171-y · Cited by 103
Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics
Deardorff, W. J., & Grossberg, G. T. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1200972 · Cited by 85
A rat model of ataxia-telangiectasia: evidence for a neurodegenerative phenotype
Quek, H., Luff, J., Cheung, K., Kozlov, S., Gatei, M. H., Lee, C. S., Bellingham, M. C., Noakes, P. G., Lim, Y. C., Barnett, N. L., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw371 · Cited by 80
Microglia and Synapse: Interactions in Health and Neurodegeneration
Šišková, Z., & Tremblay, M.-È. (2013) · Neural Plasticity · doi:10.1155/2013/425845 · Cited by 80
Posttranslational Regulation of the NLR Family Pyrin Domain-Containing 3 Inflammasome
Shim, D.-W., & Lee, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01054 · Cited by 80
Rihani, S. B. A., Darakjian, L. I., & Kaddoumi, A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00175 · Cited by 81
Wang, Y., Shan, Z., Zhang, L., Fan, S., Zhou, Y., Hu, L., Wang, Y., Li, W., & Xiao, Z. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01442-8 · Cited by 84
Targeting epigenetic regulators for inflammation: Mechanisms and intervention therapy
Zhang, S., Meng, Y., Zhou, L., Qiu, L., Wang, H., Su, D., Zhang, B., Chan, K. M., & Han, J. (2022) · MedComm · doi:10.1002/mco2.173 · Cited by 85
Tan, M., Yu, J., Jiang, T., Zhu, X., Guan, H., & Tan, L. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-131148 · Cited by 81
Pomilio, C. J., Pavía, P., Gorojod, R. M., Vinuesa, Á., Alaimo, A., Galván, V., Kotler, M. L., Beauquis, J., & Saravia, F. (2015) · Hippocampus · doi:10.1002/hipo.22503 · Cited by 82
Design, Synthesis, and Evaluation of Acrylamide Derivatives as Direct NLRP3 Inflammasome Inhibitors
Cocco, M., Miglio, G., Giorgis, M., Garella, D., Marini, E., Costale, A., Regazzoni, L., Vistoli, G., Orioli, M., Massulaha‐Ahmed, R., et al. (2016) · ChemMedChem · doi:10.1002/cmdc.201600055 · Cited by 80
Autophagy regulates MAVS signaling activation in a phosphorylation-dependent manner in microglia
Cheng, J., Liao, Y., Xiao, L., Wu, R., Zhao, S., Chen, H., Hou, B., Zhang, X., Liang, C., Xu, Y., et al. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.121 · Cited by 79
NLRP3-dependent synaptic plasticity deficit in an Alzheimer's disease amyloidosis model in vivo
Qi, Y., Klyubin, I. V., Cuello, A. C., & Rowan, M. J. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.02.016 · Cited by 80
MicroRNAs as important regulators of the NLRP3 inflammasome
Zamani, P., Oskuee, R. K., Atkin, S. L., Navashenaq, J. G., & Sahebkar, A. (2019) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.05.004 · Cited by 80
INPP5D regulates inflammasome activation in human microglia
Chou, V., Pearse, R. V., Aylward, A. J., Ashour, N., Taga, M., Terzioglu, G., Fujita, M., Fancher, S. B., Sigalov, A., Benoit, C. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42819-w · Cited by 79
Zhai, Y., Meng, X., Luo, Y., Wu, Y., Ye, T., Zhou, P., Ding, S., Wang, M., Lu, S., Zhu, L., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24295 · Cited by 79
NG2 glia are required for maintaining microglia homeostatic state
Liu, Y., & Aguzzi, A. (2019) · Glia · doi:10.1002/glia.23721 · Cited by 78
The Links between Cardiovascular Diseases and Alzheimer's Disease
Leszek, J., Вячеславовна, М. Е., Belousov, D. M., Koutsouraki, E., Szczechowiak, K., Kobusiak−Prokopowicz, M., Mysiak, A., Diniz, B. S., Somasundaram, S. G., Kirkland, C. E., et al. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200729093724 · Cited by 93
Cross-Talk of the CNS With Immune Cells and Functions in Health and Disease
Matejuk, A., Vandenbark, A. A., & Offner, H. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.672455 · Cited by 81
Migration of blood cells to β-amyloid plaques in Alzheimer's disease
Hohsfield, L. A., & Humpel, C. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2015.03.002 · Cited by 79
Microglia as a critical player in both developmental and late-life CNS pathologies
Derecki, N. C., Katzmarski, N., Kipnis, J., & Meyer-Luehmann, M. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1321-z · Cited by 78
Interferons and inflammasomes: Cooperation and counterregulation in disease
Labzin, L. I., Lauterbach, M., & Latz, E. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.05.010 · Cited by 77
Self-citationMinter, M. R., Moore, Z., Zhang, M., Brody, K. M., Jones, N. C., Shultz, S. R., Taylor, J. M., & Crack, P. J. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0341-4 · Cited by 79
Zuo, Z., Qi, F., Yang, J., Wang, X., Wu, Y., Wen, Y., Yuan, Q., Zou, J., Guo, K., & Yao, Z. B. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.02.001 · Cited by 78
Role of Inflammasomes in Neuroimmune and Neurodegenerative Diseases: A Systematic Review
Lang, Y., Chu, F., Shen, D., Zhang, W., Zheng, C., Zhu, J., & Cui, L. (2018) · Mediators of Inflammation · doi:10.1155/2018/1549549 · Cited by 80
Ben-Menachem-Zidon, O., Ben-Menahem, Y., Ben-Hur, T., & Yirmiya, R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.208 · Cited by 81
Mechanisms of action of amyloid-beta and its precursor protein in neuronal cell death
Leong, Y. Q., Ng, K. Y., Chye, S. M., Ling, A. P. K., & Koh, R. Y. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00516-y · Cited by 80
Komleva, Y. K., Chernykh, A., Lopatina, O. L., Gorina, Y. V., Lokteva, I., Salmina, A. B., & Gollasch, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.618395 · Cited by 83
Lu, J. N., Xie, S., Deng, Y., Xie, X., & Liu, Y. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.005 · Cited by 78
Cardiovascular Inflammaging: Mechanisms and Translational Aspects
Barcena, M. L., Aslam, M., Pozdniakova, S., Norman, K., & Ladilov, Y. V. (2022) · Cells · doi:10.3390/cells11061010 · Cited by 83
Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis
Zhang, S., Gao, Y., Zhao, Y., Huang, T. Y., Zheng, Q., & Wang, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00812-5 · Cited by 78
Neurovascular Inflammaging in Health and Disease
Mészáros, Á., Molnár, K., Nógrádi, B., Hernádi, Z., Nyúl‐Tóth, Á., Wilhelm, I., & Krizbai, I. A. (2020) · Cells · doi:10.3390/cells9071614 · Cited by 86
Wang, J., Wang, L., Zhang, X.-F., Xu, Y., Chen, L., Zhang, W., Liu, E., Xiao, C., & Kou, Q. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107496 · Cited by 77
Kim, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062929 · Cited by 77
Cui, Y., Yu, H., Bu, Z., Wen, L., Yan, L.-L., & Feng, J. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.894298 · Cited by 80
Fruhwürth, S., Zetterberg, H., & Paludan, S. R. (2024) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2024.578342 · Cited by 77
Shapira, R., Solomon, B., Efrati, S., Frenkel, D., & Ashery, U. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.10.007 · Cited by 80
Wei, M., Wang, L., Wu, T., Xi, J., Han, Y.-Z., Yang, X., Zhang, D., Fang, Q., & Tang, B. (2016) · BioMed Research International · doi:10.1155/2016/4323281 · Cited by 76
Shi, W., Xu, G., Zhan, X., Gao, Y., Wang, Z., Fu, S., Qin, N., Hou, X., Ai, Y., Wang, C., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2460-x · Cited by 76
Dai, Z., Chen, X.-Y., An, L.-Y., Li, C., Zhao, N., Yang, F., You, S.-T., Hou, C., Li, K., Jiang, C., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01924 · Cited by 76
Li, Z., Xu, H., Xu, Y., Lu, G., Peng, Q., Chen, J., Bi, R., Li, J., Chen, S., Li, H., et al. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13732 · Cited by 76
A guide to membrane atg8ylation and autophagy with reflections on immunity
Deretic, V. P., & Lazarou, M. (2022) · The Journal of Cell Biology · doi:10.1083/jcb.202203083 · Cited by 78
Programmed Death of Microglia in Alzheimer's Disease: Autophagy, Ferroptosis, and Pyroptosis
Qiu, Z., Zhang, H., Xia, M., Gu, J., Guo, K., Wang, H., & Miao, C. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.3 · Cited by 77
Metadata
- Authors
- Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., Gelpi, E., Halle, A., Korte, M., Latz, E., & Golenbock, D. T.
- Affiliations
- University of Bonn (DE)
- Technische Universität Braunschweig (DE)
- University of Massachusetts Chan Medical School (US)
- Center of Advanced European Studies and Research (DE)
- Corresponding author
- Heneka, Michael T.
- Latz, Eicke
- Golenbock, Douglas T.
- ORCID
- Venue
- Nature
- Published
- 2012-12-19
- Volume
- 493
- Issue
- 7434
- Pages
- 674-678
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3812809
- OpenAlex
- W1993976394
- Semantic Scholar
- 3a962c33176c94bc0dd8bfea4ebe2eb83be8a01e
- Cited by
- 2,898
- References
- 34
- Citations by year
- 2026: 274 · 2025: 270 · 2024: 273 · 2023: 270 · 2022: 306 · 2021: 314 · 2020: 261 · 2019: 203 · 2018: 187 · 2017: 147 · 2016: 117 · 2015: 112 · 2014: 99 · 2013: 62
- FWCI
- 35.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- HZI (Helmholtz Centre for Infection Research) (submittedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Max Planck Digital Library (submittedVersion)
- DZNE Pub (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health
- Genentech
- National Heart, Lung, and Blood Institute (R01HL093262)
- National Institute of General Medical Sciences (R01GM054060)
- National Institute of Allergy and Infectious Diseases (U19AI084048, R01AI083713)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- NLRP3 inflammasome, caspase-1, Alzheimer's disease, amyloid-beta, APP/PS1 mice, microglia, neuroinflammation, IL-1β, amyloid-beta clearance, spatial memory, NLRP3 knockout mice, cognitive impairment, therapeutic target
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Aged, Aged, 80 and over, Alzheimer Disease, Animals, Behavior, Animal, Brain, Carrier Proteins, Humans, Memory, Mice, Inbred C57BL, Mice, Transgenic, Phagocytosis, Gene Expression Regulation, Enzymologic, Amyloid beta-Peptides, Caspase 1, Mice, Nitric Oxide Synthase Type II, Interleukin-1beta, Inflammasomes, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
